NJ-DAIICHI-SANKYO-CO
22.7.2020 08:02:15 CEST | Business Wire | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research collaboration to enrich and further enable the development of DS-1062 and patritumab deruxtecan (U3-1402), two of Daiichi Sankyo’s lead DXd antibody drug conjugates (ADCs), in lung and breast cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200721005963/en/
The collaboration will focus on clinical and translational research, including potential combination strategies for DS-1062, a TROP2 directed DXd ADC, in patients with advanced non-small cell lung cancer (NSCLC), and for patritumab deruxtecan, a HER3 directed DXd ADC, in patients with metastatic breast cancer.
“We look forward to engaging and collaborating with the deep expertise and cutting-edge oncology research capabilities of Gustave Roussy, the premier European Cancer Center, to further advance clinical development of DS-1062 and patritumab deruxtecan,” said Antoine Yver, MD, MSc, AIHP, ACCA Paris, Global Head, Oncology R&D, Daiichi Sankyo. “This innovative research program includes two precision-medicine rich phase 2 trials designed with an adaptive approach to help determine which patients are most likely to benefit from our ADCs with optimal speed and efficiency. Combination therapy strategies will also be explored in other studies.”
“This partnership is strategic for Gustave Roussy and it brings together all the skills which are essential for top quality research in oncology. Launching clinical trials to test two promising molecules in advanced non-small cell lung cancer and metastatic breast cancer is essential for diseases which unfortunately have an increasing incidence and for which there is an urgent need to make progress,” said Prof. Jean-Charles Soria, General Director of Gustave Roussy. "It is by pushing the boundaries of innovation that we will further improve the quality of care for our patients."
About the Collaboration
Under the agreement, Daiichi Sankyo, Inc. will provide funding and support to Gustave Roussy for a comprehensive, integrative research program including clinical, translational and preclinical studies for DS-1062 and patritumab deruxtecan in lung and breast cancer, respectively.
Two adaptive phase 2 trials will be conducted, including a multicenter, open-label study to evaluate efficacy, safety and markers of response and resistance to DS-1062 in patients with advanced NSCLC who have progressed on anti-PD-1/PD-L1 therapy and platinum-doublet chemotherapy.
The second multicenter, open-label phase 2 study will evaluate the efficacy, safety and biomarkers of response and resistance to patritumab deruxtecan in patients with HER3 expressing metastatic breast cancer.
Each study will enroll up to 100 patients and will be conducted in several sites in France.
The primary endpoint for both studies is objective response rate as assessed by independent central review. Secondary endpoints include clinical benefit rate, progression-free survival, duration of response, overall survival and safety measures. The studies also will primarily be conducted to analyze biomarker expression and tumor sensitivity; the role of receptor biology in the pharmacological activity of the Daiichi Sankyo DXd ADC platform, as well as factors contributing to treatment resistance; immunogenicity and mechanism of action.
The adaptive trial design includes ongoing clinical and biomarker assessments to identify factors associated with individual patient response and the ability to fine-tune development accordingly.
Additional research to be conducted under the collaboration includes several studies exploring multiple therapeutic combinations for each ADC.
About Gustave Roussy
Gustave Roussy, Europe's leading cancer center, is a global cancer center of expertise entirely dedicated to patients. It brings together 3,100 professionals whose missions are care, research and teaching. The Institute has expertise in the management of rare cancers and complex tumors. It treats all cancers at every stage of life and offers its patients individualized care combining innovation and a humane approach. Twenty-six percent of its new patients are included in clinical trials. For more information, please visit: www.gustaveroussy.fr/en .
About DS-1062 and Patritumab Deruxtecan (U3-1402)
DS-1062 and patritumab deruxtecan (U3-1402) are two of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells.
Designed with Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is comprised of a humanized anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker. Patritumab deruxtecan is comprised of a human anti-HER3 antibody and the same payload and linker as DS-1062.
DS-1062 is currently being evaluated in a phase 1 trial in patients with advanced solid tumors that are refractory to or relapsed from standard treatment or for whom no standard treatment is available. The study is currently enrolling patients with unresectable advanced NSCLC and unresectable/advanced or metastatic triple negative breast cancer.
Patritumab deruxtecan is currently being evaluated in a phase 1 study in previously treated patients with metastatic or unresectable NSCLC. Patritumab deruxtecan is also being evaluated in a phase 1/2 study in patients with HER3 expressing metastatic breast cancer.
DS-1062 and patritumab deruxtecan are investigational agents that have not been approved for any indication in any country. Safety and efficacy have not been established.
About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com .
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005963/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bacardi Climbs to #32 Among the World’s Top Companies for Women8.10.2026 14:11:00 CEST | Press release
Family-owned Bacardi is highest-ranked spirits company Bacardi Limited has climbed to #32 on the Forbes list of the World’s Top Companies for Women 2026, rising from #60 the previous year and earning a place on the prestigious global ranking for the fifth consecutive year. The family-owned company is the highest-ranked spirits company on this year’s list and ranks #2 in the “Food, Soft Beverages, Alcohol & Tobacco” category. The recognition reflects a continued commitment to creating opportunities, championing career development and cultivating a workplace where people feel valued, empowered and able to do their best work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008127263/en/ Bacardi celebrates being the highest-ranked spirits company in the Forbes World's Top Companies for Women 2026. “The most meaningful measure of our progress is seeing talented women choose to join Bacardi, build their careers here and advance
SLB Awarded Digital Drilling Contract by TotalEnergies8.10.2026 14:04:00 CEST | Press release
Deployment will connect subsurface insights with well engineering and drilling planning workflows Global energy technology company SLB (NYSE: SLB) today announced a 15-year agreement with TotalEnergies to use the DrillPlan™ coherent well planning and engineering solutions. The agreement will support TotalEnergies’ transition to a digital planning environment, connecting subsurface insights with well planning and engineering. Enabled by SLB’s DrillPlan solutions and the expertise of both companies, the agreement marks a significant step in the companies’ digital collaboration and reflects a broader shift across the industry as operators move toward scalable, interoperable digital platforms to improve engineering and well construction execution. The DrillPlan solutions will enable TotalEnergies to streamline well design and engineering activities by integrating offset well data, trajectory designs, casing and completion inputs, and planning assumptions used throughout the well constructi
Gaétane Baudry Appointed Senior Vice President/Global General Manager, Bobbi Brown8.10.2026 14:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Gaétane Baudry as Senior Vice President/Global General Manager, Bobbi Brown, effective October 8, 2026. Based in New York, she will report to Lisa Sequino, Global President, Makeup Brands. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008525584/en/ Gaétane Baudry In this role, Gaétane will lead Bobbi Brown’s global strategy and continued evolution, strengthening the brand’s distinctive equity, advancing innovation and creativity, and deepening consumer engagement around the world. “Gaétane is an inspiring and highly collaborative leader who brings experience, energy and a strong focus on execution,” said Lisa Sequino, Global President, Makeup Brands. “Her global brand-building record, strong commercial leadership and passion for creating meaningful consumer experiences will be invaluable as Bobbi Brown builds on its unique brand equity focused
Adtran launches Mosaic One Agents to help teams easily scale operations8.10.2026 14:00:00 CEST | Press release
News summary: Rapidly growing networks, operations and customer demands call for new ways to scale expertise Mosaic One Agents provides role-specific AI agent teams for network management, customer care and business operations Agent teams use data from Adtran and third-party hardware to investigate problems in parallel while organizations retain control Adtran today launched Mosaic One Agents, a suite of AI agents designed to help organizations scale expertise across network management, customer care and business operations. Built on Mosaic One Fabric, it gives role-based agent teams access to data from Adtran and third-party networks, enabling them to investigate issues, coordinate work across teams and drive issues through to resolution. By handling time-consuming investigation, coordination and process tasks, Mosaic One Agents helps people resolve issues faster, extend their expertise across more workflows and retain control of critical network and business actions. “When something
The LYCRA Company to Spotlight Renewable LYCRA® Fiber and Textile-to-Textile Circularity at Textile Exchange Conference 20268.10.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in fiber and technology solutions for the apparel and personal care industries, will showcase Renewable LYCRA® fiber and its work to advance textile-to-textile recycling at Textile Exchange Conference 2026. The conference takes place October 12–16, at the Vancouver Convention Centre in Vancouver, Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008178765/en/ At the Textile Exchange Conference 2026, The LYCRA Company will showcase Renewable LYCRA® fiber and its progress in advancing textile-to-textile recycling. This year's theme, "The Implementation Era," focuses on scaling what works across businesses, supply systems, and landscapes. At the conference, The LYCRA Company will highlight its work with partners across the value chain, helping to shape the future for textiles through renewable fiber solutions, circular innovation, and strategic industry partnerships. “Bringing more rec
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom